摘要
目的对尿激酶静脉溶栓后联合阿司匹林、氯吡格雷抗血小板聚集治疗早期脑梗死的临床疗效进行分析和探讨。方法以我院2015年12月~2017年1月期间收治的44例早期脑梗死患者为研究对象,根据随机双盲原则将患者分为观察组和对照组两组,每组22例。两组患者均接受相同的尿激酶静脉溶栓并在24小时后与阿司匹林口服治疗,与此同时,联合给予观察组患者氯吡格雷抗血小板聚集治疗,比较两组患者临床疗效。结果相较于对照组患者,观察组患者治疗后的神经功能缺损评分、血清hs-CRP水平以及各血液流变学指标值均更优(P<0.05);此外,观察组患者临床治疗总有效率显著高于对照组患者、不良反应总发生率显著低于对照组患者(P<0.05)。结论尿激酶溶栓后与阿司匹林、氯吡格雷联合使用是治疗早期脑梗死的有效途径,具有有效率高、不良反应少等优势,推荐使用。
To analysis and discuss the effect of Urokinase intravenous thrombolysis combined with aspirinand clopidogrel antiplatelet aggregation on the treatment of early cerebral infarction. Methods Forty four patients with early cerebral infarction hospitalized from December 2015 to January 2017 were enrolled. All cases were randomly divided into ob-servation group and control group with 22 patients respectively. To compare the clinical effects, both two groups were given the same Urokinase intravenous thrombolysis and aspirin oral therapy, while the observation group received additional clopi-dogrel antiplatelet aggregation. Results Compared to the control group, Neurological deficit score, serum hs-CRP levels, and hemorheology index values of the observation group were better than those of control group (P〈0 . 05). Moreover,the total efficient and incidence of adverse reactions of observation were respectively higher and lower than that of control group (P〈0. 05). Conclusions Urokinase intravenous thrombolysis combined with aspirin and clopidogrel is an high efficient way to treat the early cerebral infarction, and could reduce the adverse reactions.
出处
《临床研究》
2018年第1期84-86,共3页
Clinical Research